Introduction {#S1}
============

Brain microtubules were first isolated and characterized in the 1970s ([@B76]). This study revealed the presence of a main protein, tubulin, and several others described as microtubule-associated proteins (MAPs) in these structures. One of these MAPs, tau, was first characterized by Kirschner's group ([@B75]). Similar to other MAPs, the function of tau was found to be related to an increase in microtubule stabilization ([@B21]), which prevents cell proliferation and facilitates neuronal differentiation. Recent discoveries about partners (End binding proteins 1 and 3, tRNA), different subcellular localizations (nucleus, nucleolus, plasma membrane, dendrites and dendritic spines) or association with cellular organelles (ribosomes, endoplasmic reticulum and the Golgi apparatus) for tau suggest additional roles. According to these studies, tau should be implicated on mechanisms of synaptic plasticity, structural architecture of heterochromatin, chromosome stability or regulating the cellular transcriptome (for more detail see review [@B67]).

Although tau is mainly an intracellular protein, there are reports indicating that extracellular tau is present in brain interstitial fluid ([@B79]), its amount decreasing in this medium during sleep ([@B45]). Secreted tau may be implicated in some features of sleep ([@B9]; [@B45]). However, independently of this notion, secreted tau protein is present *in vivo*, and its secretion appears to be regulated.

Tau Secretion and Its Regulation {#S2}
================================

The presence of extracellular tau suggests that it is secreted under physiological conditions. In this regard, it has been proposed that intracellular tau is released upon an increase in neuronal activity ([@B55]; [@B80]). In addition to neuron activity-dependent tau secretion, the extracellular form of the protein may arise by other mechanisms, such as neuron death ([@B28]), intracellular tau accumulation ([@B65]), a tauopathy ([@B13]), or modulation by tau mutations ([@B40]). In the case of neuron death, intracellular proteins like tau are released into the extracellular space.

Intracellular tau accumulation can arise due to aging. In this regard, tau accumulation in older adults is associated with hippocampal hyperactivity ([@B37]). Also, an increase in intracellular levels of tau can result from pathological disorders related to a decrease in the turnover of this protein. This reduction can be caused by impaired tau degradation through two main systems, the ubiquitin-proteasome pathway and the autophagy-lysosomal pathway ([@B74]; [@B11]; [@B44]; [@B31]). Recently, a third degradative pathway, the endolysosomal system, has been proposed for neurodegenerative disorders such as AD or Parkinson's disease ([@B71]). Rab35 and the endosomal sorting complex required for transport (ESCRT) machinery should be involved in the delivery of tau to lysosomes via early endosomes and multivesicular bodies. Intracellular tau accumulation may facilitate post-translational modifications, like phosphorylation or truncation, in the protein ([@B3]), and the modified tau isoform can also be secreted.

Hyperphosphorylation is one of the most important post-translational modifications in AD and related tauopathies ([@B48]). An increase in phosphorylation at T181 ([@B70]) or T231 ([@B34]) has been described in the cerebrospinal fluid of AD patients, although a decrease with the progression of AD has also been reported ([@B33]). Thus, a tau mutant mimicking phosphorylation is more efficiently secreted than one mimicking dephosphorylation in Hela cells ([@B53]). However, it is still unclear whether phosphorylation regulates tau secretion, since both phosphorylated and unphosphorylated tau species have been detected in the extracellular space. Studies carried out in primary cortical neurons showed the release of unphosphorylated tau in control conditions ([@B55]), while other groups have reported that cortical neurons secrete phosphorylated and unphosphorylated Tau species in response to various insults ([@B53]). Further research is needed to elucidate how tau phosphorylation contributes to the secretion of this protein. However, one point to keep in mind is the observation that extracellular tau is dephosphorylated in the AD brain by tissue Non-specific alkaline phosphatases ([@B19]).

Tau Secretion in Cell Culture Models {#S3}
====================================

The transfer of tau in Non-neuronal cell cultures may take place upon tau secretion ([@B24]), and in a direct way it has been demonstrated that the accumulation of tau in Non-neuronal cells promotes its secretion to the extracellular space in nacked (free) form or via membrane vesicles ([@B65]). This secretion could occur by accumulation of the whole tau molecule or by accumulation of tau fragments ([@B51]). Post-translational modifications like phosphorylation or truncation may regulate tau secretion in Non-neuronal cell models ([@B19]; [@B53]). Also, secretion of truncated tau forms has been reported in neuronal cells ([@B43]; [@B39]). In this regard, a number of mechanisms explaining the secretion of truncated (and/or aggregated) tau and tau in free form ([@B42]) have been put forward.

Regarding the factors involved in the secretion of tau in cell culture models, End-binding proteins bind to the N-terminal end of human tau protein ([@B60]). This observation suggests that the interaction of EB proteins with tau facilitates the localization of tau close to cellular membrane and its further secretion. However, more analysis is needed to confirm this notion.

Possible Mechanisms of Tau Secretion {#S4}
====================================

The molecular mechanisms responsible for the secretion of tau in its different forms: unmodified, phosphorylated, truncated, etc, are unclear. It has been postulated that secretion takes place through a Non-vesicular (free protein) secretory pathway, because tau lacks a signal sequence to regulate its transport to the endoplasmic reticulum, a step needed in the conventional secretary pathway ([@B78]). On the other hand, the Golgi dynamics in neurons has been linked to the regulation of tau secretion ([@B49]). Also, mitochondria damage in neurons and Non-neuronal cells may also be involved in the modulation of tau secretion ([@B61]). Although it is not clear how tau can be localized at the cell membrane, several reports demonstrate its presence at the membrane ([@B7]; [@B1]), a localization that could favor its further secretion. Also, tau is found present at various cell protrusions like dendritic spines ([@B38]), growth cones ([@B20]), axonal grains ([@B18]) and presynaptic compartments ([@B82]). In the postsynaptic compartment, tau binds to presynaptic vesicles through the transmembrane vesicle protein synaptogyrin-3, as found in the brain of AD patients ([@B46]). A reduction of synaptogyrin-3 prevents the association of presynaptic tau with vesicles and may facilitate neurotransmitter release ([@B46]).

In contrast, an unconventional secretory pathway is the one involving protein secretion through extracellular vesicles such as exosomes and microvesicles. This mechanism has been proposed to decrease the levels of some intracellular proteins ([@B66]). [@B73] have demonstrated that tau may be released via exosomes by neurons or cultured cells and the release of exosomes is enhanced by neuronal activity. Furthermore, [@B2] have suggested that microglia may phagocytize tau-containing neurons and would secrete tau in exosomes, in order to facilitate its propagation to neurons. Recently, [@B41] have characterized a mechanism in which hyperphosphorylated tau is secreted through direct translocation across the plasma membrane. PI(4,5)P~2~ and proteoglycans are involved in this secretion process.

Additionally, the involvement of larger extracellular vesicles, ectosomes, has been proposed ([@B22]).

Multivesicular bodies (MVBs; late endocytic compartments) can fuse with the plasma membrane to release intraluminal vesicles into the extracellular medium, and once secreted, these vesicles are called the exosomes ([@B25]) ([Figure 1](#F1){ref-type="fig"}). In contrast, microvesicles arise by outward budding of the plasma membrane ([@B66]; [@B26]).

![Schematic Representation of Cell-to-Cell Transmission of Tau Pathology. Tau seeds are released from neurons by different exocytosic mechanisms (exosome, secretion and neuronal death). The released tau is taken up by neurons or glial cells by a variety of mechanisms (mediated by receptors, micropinocytosis, phagocytosis and/or membrane fusion of exosomes. RAGE: receptor for advanced glycation endproducts. M1/M3: muscarinic receptors.](fnins-13-00698-g001){#F1}

Exosomes and Interactions With the Cell Surface of Target Cells {#S5}
===============================================================

Exosomes are defined as signaling organelles involved in health or in disease signaling pathways ([@B15]). Measuring between 30 and 150 nm, these extracellular vesicles were first described almost 40 years ago ([@B69]). They are composed by a membrane that contains proteins like tetraspanins, flotillin and cell-specific receptors, and lipid rafts containing cholesterol, sphingomyelin and ceramide ([@B17]). The vesicle itself holds different types of proteins, nucleic acids (like miRNAs) or protein nucleic acid complexes depending of the cell types from which they are released ([@B15]). Also, exosomes can also be found in several body fluids like plasma, saliva, urine, cerebrospinal fluid, amniotic fluid, colostrum, breast milk, synovial fluid, semen and pleural ascites ([@B15]; [@B47]). For this reason, exosomes have been used as biomarkers of different diseases. Recently, a precipitation/immunoaffinity system has been developed to isolate neuron-derived as well as astrocyte-derived exosomes in the blood of Alzheimer's disease patients. Results from these studies suggest that neuronal exosomes from blood plasma and that measurement of certain forms of tau in neuronal exosomes can be used as a diagnostic and prognostic biomarker to the disease ([@B27]; [@B30]).

The membranes of some types of exosomes contain proteins with the capacity to interact with the plasma membrane proteins of their target cells. For instance, B-lymphocytes exosomes bear integrin that are capable to interact with fibroblasts ([@B14]). However, less specific links, mainly through the extracellular matrix ([@B15]), may contribute to the interaction with target cells. In general, several mechanisms have been put forward to explain the interaction of exosomes with target cells that results in cell membrane fusion, phagocytosis, macropinocytosis, and receptor-mediated endocytosis ([@B47]) ([Figure 1](#F1){ref-type="fig"}).

Neuron-Derived Exosomes and Neurodegeneration {#S6}
=============================================

Neuron-derived exosomes containing specific proteins related to neurological disorders can be released from the neurons affected. In the case of AD, the presence of exosomes containing tau or amyloid-β peptide has been reported. Exosomes can transport the amyloid-β peptide or fragments of its precursor protein (APP; [@B56]; [@B63]; [@B52]; [@B59]). Furthermore, aggregated tau has been reported in brain exosomes of mouse models of tauopathy ([@B4]; [@B54]). In these animal models, neuronal exosomes containing human mutated tau are toxic to the recipient neurons *in vivo* ([@B77]). Also, tau exosomes could be used as biomarkers not only for AD but also Down syndrome and Parkinson's disease ([@B64]; [@B32]). With respect to phosphorylation, tau secreted by exosomes is phosphorylated at some AD epitopes ([@B35]; [@B57]).

Indeed, it has been suggested that the tau efflux from the Central Nervous System via exosomes is increased in Parkinson's disease but not in AD ([@B64]). However, exosomes containing tau protein have been found in human biofluids in AD patients ([@B23]; [@B30]) and the release and *trans*-synaptic transmission of tau via exosomes has been also described ([@B73]).

Tau Transmission From Cell to Cell {#S7}
==================================

The exact mechanism of tau release is unclear, and some studies have demonstrated that both vesicle-bound and soluble free extracellular populations of tau exist ([@B57]; [@B39]; [@B73]). Furthermore, neuron death results in the release of tau into the extracellular space. Soluble-free tau protein can interact with M1/M3 muscarinic receptors which may be present, not only in neurons but also in some glia ([@B58]). The reception of tau by these receptors may lead to an increase in intracellular calcium ([@B29]; [@B19]). On the other hand, extracellular tau reacts with fractalkine receptors in microglia ([@B5]; [@B50]) and this interaction may contribute to tau propagation ([@B2]).

Tau propagation implicates its cellular uptake by surroundings cells. Clathrin-mediated endocytosis, micropinocytosis, or direct membrane fusion have been proposed as possible mechanisms of tau uptake ([@B12]; [@B8]; [@B46]).

The discovery of tau spreading has prompted several researchers to focus on the development of tau antibodies as immunotherapies to block the cell-to-cell transmission of pathological tau ([@B6]; [@B10]; [@B81]; [@B16]).

Future {#S8}
======

Further research should address exosomes containing tau. These vesicles contain proteins and nucleic acids and sometimes complexes of both. Tau is a nucleic acid-binding protein ([@B72]; [@B68]) and, inside the exosome, it can be bound to a specific nucleic acid. This binding could result in conformational changes in the tau molecule, which would lead to diverse tau-prion strains ([@B36]; [@B62]). In summary, a better characterization of tau isoforms present in exosomes would help us to understand the mechanism of tau propagation.
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